Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Effects of Albumin on Survival after a Hepatic Encephalopathy Episode: Randomized Double-Blind Trial and Meta-Analysis

  • Ventura Cots, Meritxell
  • Simon-Talero Horga, Macarena
  • Poca Pastor, Ma Antonia
  • Ariza, Xavier
  • Masnou, Helena
  • Sanchez, Jordi
  • Torrens Buscató, Maria Margarita
  • Genescà Ferrer, Joan
Albúmina; Assaig clínic; Metanàlisi, Albumin; Clinical trial; Meta-analysis, Albúmina; Ensayo clínico; Metaanálisis, No therapies have been proven to increase survival after a hepatic encephalopathy (HE) episode. We hypothesize that two doses of albumin could improve 90-day survival rates after a HE episode. Methods: (1) A randomized double-blind, placebo-controlled trial (BETA) was conducted in 12 hospitals. The effect of albumin (1.5 g/kg at baseline and 1 g/kg on day 3) on 90-day survival rates after a HE episode grade II or higher was evaluated. (2) A meta-analysis of individual patient’s data for survival including two clinical trials (BETA and ALFAE) was performed. Results: In total, 82 patients were included. Albumin failed to increase the 90-day transplant-free survival (91.9% vs. 80.5%, p = 0.3). A competing risk analysis was performed, observing a 90-day cumulative incidence of death of 9% in the albumin group vs. 20% in the placebo (p = 0.1). The meta-analysis showed a benefit in the albumin group, with a lower rate of clinical events (death or liver transplant) than patients in the placebo (HR, 0.44; 95% CI, 0.21–0.82), when analyzed by a competing risk analysis (90-days mortality rate of 11% in the albumin group vs. 30% in the placebo, p = 0.02). Conclusions: Repeated doses of albumin might be beneficial for patient’s survival as an add-on therapy after an HE episode, but an adequately powered trial is needed., This work was supported by grants ICI14/00352 and PI/18/00947 from Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (ERDF/ESF, “Investing in your future”—Una manera de hacer Europa). MVC and MST are both recipients of Juan Rodes grants from ISCIII. JG is a recipient of a research intensification grant from the ISCIII. CIBERehd is supported by ISCIII. ACS is a recipient of the Rio Hortega grant from ISCIII. The work was independent of all funding.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Effects of albumin on survival after a hepatic encephalopathy episode, Randomized double-blind trial and meta-analysis

  • Ventura-Cots, Meritxell|||0000-0001-9513-2855
  • Simón Talero, Macarena|||0000-0002-1409-3936
  • Poca Sans, Maria|||0000-0002-0235-1395
  • Ariza, Xavier
  • Masnou, Helena|||0000-0003-0632-1393
  • Sánchez Delgado, Jordi|||0000-0002-5217-6492
  • Llop, Elba
  • Cañete Hidalgo, Nuria|||0000-0001-9501-7590
  • Martín-Llahí, Marta
  • Amador, Alberto
  • Martínez, Javier
  • Clemente-Sanchez, Ana
  • Puente, Angela
  • Torrens, Maria|||0000-0003-3479-0066
  • Alvarado-Tapias, Edilmar|||0000-0003-2036-6133
  • Napoleone, Laura
  • Miquel Planas, Mireia|||0000-0003-4566-4962
  • Ardèvol Ribalta, Alba
  • Casas, Meritxell|||0000-0001-7227-7277
  • Calleja, Jose Luis|||0000-0002-2265-6591
  • Solé Martí, Cristina|||0000-0002-6104-8345
  • Soriano, German|||0000-0002-9267-6811
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
No therapies have been proven to increase survival after a hepatic encephalopathy (HE) episode. We hypothesize that two doses of albumin could improve 90-day survival rates after a HE episode. Methods: (1) A randomized double-blind, placebo-controlled trial (BETA) was conducted in 12 hospitals. The effect of albumin (1.5 g/kg at baseline and 1 g/kg on day 3) on 90-day survival rates after a HE episode grade II or higher was evaluated. (2) A meta-analysis of individual patient's data for survival including two clinical trials (BETA and ALFAE) was performed. Results: In total, 82 patients were included. Albumin failed to increase the 90-day transplant-free survival (91.9% vs. 80.5%, p = 0.3). A competing risk analysis was performed, observing a 90-day cumulative incidence of death of 9% in the albumin group vs. 20% in the placebo (p = 0.1). The meta-analysis showed a benefit in the albumin group, with a lower rate of clinical events (death or liver transplant) than patients in the placebo (HR, 0.44; 95% CI, 0.21-0.82), when analyzed by a competing risk analysis (90-days mortality rate of 11% in the albumin group vs. 30% in the placebo, p = 0.02). Conclusions: Repeated doses of albumin might be beneficial for patient's survival as an add-on therapy after an HE episode, but an adequately powered trial is needed.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Effects of Albumin on Survival after a Hepatic Encephalopathy Episode: Randomized Double-Blind Trial and Meta-Analysis

  • Ventura Cots, Meritxell
  • Simon-Talero Horga, Macarena
  • Poca Pastor, Ma Antonia
  • Ariza, Xavier
  • Masnou, Helena
  • Sanchez, Jordi
  • Torrens Buscató, Maria Margarita
  • Genescà Ferrer, Joan
Albúmina; Assaig clínic; Metanàlisi, Albumin; Clinical trial; Meta-analysis, Albúmina; Ensayo clínico; Metaanálisis, No therapies have been proven to increase survival after a hepatic encephalopathy (HE) episode. We hypothesize that two doses of albumin could improve 90-day survival rates after a HE episode. Methods: (1) A randomized double-blind, placebo-controlled trial (BETA) was conducted in 12 hospitals. The effect of albumin (1.5 g/kg at baseline and 1 g/kg on day 3) on 90-day survival rates after a HE episode grade II or higher was evaluated. (2) A meta-analysis of individual patient’s data for survival including two clinical trials (BETA and ALFAE) was performed. Results: In total, 82 patients were included. Albumin failed to increase the 90-day transplant-free survival (91.9% vs. 80.5%, p = 0.3). A competing risk analysis was performed, observing a 90-day cumulative incidence of death of 9% in the albumin group vs. 20% in the placebo (p = 0.1). The meta-analysis showed a benefit in the albumin group, with a lower rate of clinical events (death or liver transplant) than patients in the placebo (HR, 0.44; 95% CI, 0.21–0.82), when analyzed by a competing risk analysis (90-days mortality rate of 11% in the albumin group vs. 30% in the placebo, p = 0.02). Conclusions: Repeated doses of albumin might be beneficial for patient’s survival as an add-on therapy after an HE episode, but an adequately powered trial is needed., This work was supported by grants ICI14/00352 and PI/18/00947 from Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (ERDF/ESF, “Investing in your future”—Una manera de hacer Europa). MVC and MST are both recipients of Juan Rodes grants from ISCIII. JG is a recipient of a research intensification grant from the ISCIII. CIBERehd is supported by ISCIII. ACS is a recipient of the Rio Hortega grant from ISCIII. The work was independent of all funding.